Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){Le(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

Compare

7.22 -0.10 (-1.37%)

At close: 30 August at 4:00 pm GMT-4

7.25 +0.03 (+0.42%)

After hours: 30 August at 6:04 pm GMT-4

Key events

Line

Candle

Baseline

Mountain

Bar

Advanced chart

Loading Chart for INO

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous close 7.32
Open 7.41
Bid 6.13 x 100
Ask 8.22 x 100
Day's range 7.13 - 7.55
52-week range 3.84 - 14.75
Volume 207,284
Avg. Volume 362,865
Market cap (intra-day) 187.462M
Beta (5Y monthly) 0.89
PE ratio (TTM) --
EPS (TTM) -5.07
Earnings date 7 Nov 2024 - 11 Nov 2024
Forward dividend & yield --
Ex-dividend date --
1y target est 16.75

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

www.inovio.com

127

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Biotechnology

Industry

More about Inovio Pharmaceuticals, Inc.

Recent news: INO

All SEC filings

Corporate changes and voting matters

Periodic financial reports

Proxy statements

Compare

Select to analyse similar companies using key performance metrics; select up to four stocks.

INOInovio Pharmaceuticals, Inc.

7.22

-1.37%

Mkt cap 187.462M

Industry Biotechnology

VXRTVaxart, Inc.

0.8669

+1.75%

Mkt cap 197.167M

Industry Biotechnology

NVAXNovavax, Inc.

12.38

+8.60%

Mkt cap 1.982B

Industry Biotechnology

SRNESorrento Therapeutics, Inc.

0.0060

0.00%

Mkt cap 3.308M

Industry Biotechnology

IBIOiBio, Inc.

1.9700

+5.35%

Mkt cap 16.989M

Industry Biotechnology

OCGNOcugen, Inc.

1.3000

+2.36%

Mkt cap 374.215M

Industry Biotechnology

BCRXBioCryst Pharmaceuticals, Inc.

8.69

+0.70%

Mkt cap 1.798B

Industry Biotechnology

MRNAModerna, Inc.

77.40

-0.24%

Mkt cap 29.752B

Industry Biotechnology

VIRVir Biotechnology, Inc.

8.26

-0.48%

Mkt cap 1.129B

Industry Biotechnology

BNTXBioNTech SE

88.22

+0.71%

Mkt cap 20.976B

Industry Biotechnology

GERNGeron Corporation

4.7500

+4.17%

Mkt cap 2.863B

Industry Biotechnology

Statistics: INO

Valuation measures

As of 30/08/2024

Market cap

187.46M
Enterprise value

90.02M
Trailing P/E

--
Forward P/E

--
PEG ratio (5-yr expected)

--
Price/sales (ttm)

291.60
Price/book (mrq)

1.94
Enterprise value/revenue

152.10
Enterprise value/EBITDA

--

Financial highlights

Profitability and income statement

Profit margin

0.00%
Return on assets (ttm)

-39.91%
Return on equity (ttm)

-91.42%
Revenue (ttm)

591.86k
Net income avi to common (ttm)

-121.64M
Diluted EPS (ttm)

-5.07

Balance sheet and cash flow

Total cash (mrq)

110.42M
Total debt/equity (mrq)

13.42%
Levered free cash flow (ttm)

-70.59M

Research analysis: INO

People also watch

VXRT Vaxart, Inc.

0.8669

+1.75%

NVAX Novavax, Inc.

12.38

+8.60%

MRNA Moderna, Inc.

77.40

-0.24%

SRNE Sorrento Therapeutics, Inc.

0.0060

0.00%

CODX Co-Diagnostics, Inc.

1.3900

-2.11%

BNTX BioNTech SE

88.22

+0.71%

IBIO iBio, Inc.

1.9700

+5.35%

AZN AstraZeneca PLC

87.62

+0.37%

NKLA Nikola Corporation

6.63

+0.91%

VIR Vir Biotechnology, Inc.

8.26

-0.48%

WKHS Workhorse Group Inc.

0.6800

-2.17%

GILD Gilead Sciences, Inc.

79.00

-0.57%

OCGN Ocugen, Inc.

1.3000

+2.36%

SPCE Virgin Galactic Holdings, Inc.

6.69

+1.67%

REGN Regeneron Pharmaceuticals, Inc.

1,184.69

+0.49%

KODK Eastman Kodak Company

5.28

+0.57%

Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance (2024)

Full-time employees

Fiscal year ends

Sector

Industry

Profitability and income statement

Balance sheet and cash flow